Hemophilia Treatment Market Achieved USD 12.1 billion in 2021 and is Estimated to reach USD 18.3 billion in 2029 | Size, Share & Industry Report

Hemophilia Treatment Market

The Hemophilia Treatment Market Touched USD 12.1 billion in 2021 and is projected to reach USD 18.3 billion in 2029 and the market will grow at a CAGR of 5.3%.

For Additional Insights, Click to Access Complete Report - https://www.gmiresearch.com/report/hemophilia-treatment-market-analysis-industry-research/

The factors driving the growth of Hemophilia Treatment Market includes increasing incidence of Hemophilia disorder across the globe, rising focus on improving quality of patient's life, growing rate of diagnostic screening and favorable Government regulations regarding hemophilia treatment. According to the report published by National Library of Medicine, the number of people living with hemophilia in India were estimated around 2 per 1,00,000 male births and 277 new cases of hemophilia are recorded every year, which is pushing the demand for hemophilia treatment products in the Indian market. Moreover, rising popularity of replacement therapy and gene therapy, growing demand for recombinant and plasma derived products across the globe, advancements in genetic research, Governments grants to the medical institutions and rapid urbanization, are some of the additional factors supplementing the Hemophilia Treatment Market share. In addition, the increasing investments by leading players on research and development, rising disposable incomes and growing population growth rates, are further propelling the Hemophilia Treatment Market size.

However, growth of the Hemophilia Treatment Market is hindered due to high-cost treatment and inadequate knowledge about hemophilia treatment.

The major players operating in the Hemophilia Treatment Market are Kedrion S.p.A, Pfizer Inc., Bayer AG, Baxter, Grifols, S.A., CSL Limited, Biogen, Hospira, Inc, Octapharma AG and Novo Nordisk A/S, among others. 

Based on Product, the Recombinant coagulation factor concentrates segment is predicted to grow at a significant CAGR during the forecast period

Availability of recombinant derived products and rising investments by companies on research and development, are propelling segment's growth.

Based on Type, the Hemophilia A segment is projected to expand at a remarkable CAGR over the forecast period

Rising prevalence of hemophilia, A across the globe, is pushing the demand for hemophilia treatment solutions. 

Based on Region, the North American region is anticipated to capture the largest market share during the forecast period

As per the Hemophilia Treatment Market Analysis, increasing incidences of bleeding disorder, growing adoption of prophylaxis treatment, rise in Government's allocation to medical institutes for genetic research and high per capita incomes, are some of the important factors augmenting the market growth in North American region.

Key Developments

2022, Novo Nordisk planned to expand its product offerings to support Canadians suffering with hemophilia A. The expansion made ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Doman Truncated), PEGylated) and ZONOVATE® (Antihemophilic Factor (Recombinant, B-Domain Truncated) publicly available through Canadian Blood Services starting April.1, 2022.
In 2021, Grifols donated 240 million international units (IU) of blood clotting factors for eight years to treat approximately 3,000 bleeding disorder patients.
In 2021, CSL Limited announced to close a license agreement for a hemophilia B gene therapy candidate which was positive, but there are still risks aligned with competition and regulatory approvals.

Market Segmentation

Segmentation by Product

Plasma derived coagulation factor concentrates
Factor VIII
Factor IX
Factor XIII
Activated prothrombin complex concentrate
Von willebrand factor
Recombinant coagulation factor concentrates
Factor VIII
Factor IX
Von willebrand factor
Desmopressin
Antifibrinolytic agents

Segmentation by Type

Hemophilia A
Hemophilia B
Hemophilia C

Segmentation by Region

Asia Pacific
China
Japan
India
Rest of APAC

North America
United States of America
Canada

Europe
United Kingdom
Germany
France
Spain
Rest of Europe

RoW
Brazil
South Africa
Saudi Arabia
UAE

About GMI Research

GMI Research is a market research and consulting firm which provides market insights and intelligence across 12 major sectors helping our clients in making effective investment and business decisions.

Media Contact
Company Name: GMI RESEARCH
Contact Person: Sarah Nash
Email: enquiry@gmiresearch.com
Phone: Europe - +353 1 442 8820; US - +1 860 881 2270
Address: Dublin, Ireland
Website: https://www.gmiresearch.com/

Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate, Dublin D18 Y3X2, Ireland

GMI Research's leadership team with extensive experience in research and consulting together with our research and domain expertise creates a strong value proposition to create solutions that addresses our clients business problems and add significant value to long lasting relationship.

This release was published on openPR.